The standardised treatment of pulmonary TB: outcomes, problems and suggestions Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005
TB and COVID-19 – a dangerous new combination? Source: ERS webinar 2021: TB and COVID-19 – a dangerous new combination? Year: 2021
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries Source: Eur Respir J, 51 (6) 1800387; 10.1183/13993003.00387-2018 Year: 2018
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011
Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Tuberculosis (TB), mortality - efficiency of new control / treatment strategies Source: Annual Congress 2003 - Control of tuberculosis Year: 2003
The burden of TB–HIV in the EU: how much do we know? A survey of surveillance practices and results Source: Eur Respir J 2011; 38: 1374-1381 Year: 2011
Childhood tuberculosis in Israel: epidemiological trends and treatment outcomes, 1999–2010 Source: Eur Respir J 2013; 41: 1157-1162 Year: 2013
TB drug resistance in high-incidence countries Source: Eur Respir Mon 2012; 58: 95-110 Year: 2012
Tuberculosis: cost of illness in Germany Source: Eur Respir J 2012; 40: 143-151 Year: 2012
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
European framework to decrease the burden of TB/HIV Source: Eur Respir J 2004; 24: 493-501 Year: 2004
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012
Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen? Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
Has the time come to shorten TB treatment and TB preventive therapy? Source: Virtual Congress 2021 – Respiratory infections Year: 2021